<a href="https://laohu8.com/S/VERU">Veru Inc.</a> Settles $8.8 Million Debt with Onconetix Through Cash, Preferred Stock, and Warrants Under Amended Loan Agreement
**Veru Inc. Settles Outstanding Promissory Notes with Onconetix, Inc.** Veru Inc. has announced the termination of its outstanding loan agreements with Onconetix, Inc. (formerly Blue Water Vaccines Inc.), following a recently executed Settlement Agreement. As of September 22, 2025, a total of $8.8 million was owed to Veru under two promissory notes related to a previous asset purchase. Under the terms of the settlement, Veru agreed to accept a reduced cash payment of approximately $6.3 million, along with 3,125 shares of Onconetix's Series D Convertible Preferred Stock (valued at $1,000 per share) and 846,975 warrants to purchase common stock, in full satisfaction of all outstanding obligations. The transaction was completed on September 24, 2025, with all related agreements and notes officially terminated upon payment. There is no assurance as to the timing or amount of any future proceeds Veru may receive from the preferred shares or warrants.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-029912), on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.